@ARTICLE{10.3389/fcvm.2020.00152, AUTHOR={Grewal, Sarah and Jankelson, Lior and van den Broek, Marcel P. H. and Cour, Martin and Bachmann, Gloria and Kostis, John B. and Misra, Kamana}, TITLE={QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment}, JOURNAL={Frontiers in Cardiovascular Medicine}, VOLUME={7}, YEAR={2020}, URL={https://www.frontiersin.org/articles/10.3389/fcvm.2020.00152}, DOI={10.3389/fcvm.2020.00152}, ISSN={2297-055X}, ABSTRACT={Women have higher risk for developing TdP in response to ventricular repolarization prolonging drugs. Hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients. While an overall prolonged QTc has been reported in COVID-19 patients undergoing these treatments, the question on even higher QTc elevation risk in thousands of female COVID-19 patients undergoing these treatments remains unanswered. We therefore explore data reported and shared with us to evaluate safety and efficacy of antimalaria pharmacotherapies in female COVID-19 patients. Although we observed longer mean QTc intervals in female patients in 2 of the 3 cohorts reviewed, the sex disproportionality in COVID-19 hospitalizations precludes a clear sex mediated QTc interval elevation risk association in the female COVID-19 patients undergoing acute treatment regimens. Adoption of study designs that include observation of sex mediated differential triggering of cardiac electrical activity by these drugs is warranted.} }